Evolus, Inc.
https://www.evolus.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Evolus, Inc.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
Korea Q3 Roundup: Mixed Results Amid Focus On Obesity, New Drugs
As Korean firms report quarterly earnings, Hanmi is stepping up the development of obesity drugs, Daewoong unveils plans to boost sales of in-house new drugs, GC Biopharma’s immunoglobulin undergoes the US approval process and Ildong has set up a new R&D-focused subsidiary.
Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Pharmaceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- ALPHAEON Corporation
- AEON Biopharma, Inc.
- SCH-AEON, LLC
- Strathspey Crown Holdings, LLC
- Strathspey Crown Holdings Group, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice